Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 19/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 16/20 | 0.56 |
| ▸ | FGFR4 | P22455 | 15/20 | 0.56 |
| ▸ | VEGFA | P15692 | 5/20 | 0.56 |
| ▸ | FLT1 | P17948 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17175552 | 0.88 | FGFR3 (0.60) | FGFR3FGFR1FGFR2FGFR4VEGFA | |
| SCHEMBL14901120 | 0.86 | FGFR3 (0.54) | FGFR3FGFR1FGFR2FGFR4VEGFA | |
| SCHEMBL17175166 | 0.83 | FGFR3 (0.66) | FGFR3FGFR1FGFR2FGFR4VEGFA | |
| SCHEMBL18738953 | 0.81 | FGFR3 (0.72) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14905406 | 0.77 | FGFR3 (0.59) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901179 | 0.76 | FGFR3 (0.54) | FGFR3FGFR1FGFR2FGFR4VEGFA | |
| SCHEMBL14901222 | 0.76 | FGFR3 (0.55) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901141 | 0.75 | FGFR3 (0.54) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901156 | 0.75 | FGFR3 (0.47) | FGFR3FGFR1FGFR2FGFR4VEGFA | |
| SCHEMBL14905223 | 0.74 | FGFR1 (0.59) | FGFR3FGFR1FGFR2FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855480-B1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2019-06-26 | — | — | EP | disclosed |
| US-10272087-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170000796-A1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-01-05 | — | — | US | disclosed |
| US-9447098-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150291589-A1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291589-A1 | PTERIDINES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885FGFR1 1/4885FGFR2 3/4885 |
| US-10272087-B2 | Pteridines as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885FGFR1 1/4885FGFR2 3/4885 |
| US-20170000796-A1 | PTERIDINES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885FGFR1 1/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.